Engineering of rare, naturally occurring non-developable antibodies into powerful therapeutics
Rare antibodies with unusual structures and ultra-long CDRs have the potential to bind to difficult-to-access epitopes (e.g., GPCRs, ion channels), and thus offer a unique mode of action. But since they are considered non-developable, they are often excluded from rationally designed antibody libraries or neglected in developability-driven AI selections. This application note demonstrates how tailored […]
Novel NKG2D-targeting bispecific antibodies improve B cell lymphoma killing
In collaboration with the universities of Kiel, Munich, and Braunschweig, a novel bispecific antibody CD20xNKG2D was developed to enhance lymphocyte recruitment and mediate killing of B cell lymphoma cells. Read more
PROxAbs: Next generation PROTACs to access difficult targets
In collaboration with YUMAB, scientists from Merck KGaA have developed a PROTAC-Antibody shuttle (PROxAb) to improve efficacy and therapeutic applicability of PROTACs. Read more
Automated customized antibody purification with flowbot ONE
Automating small-scale purification, e.g., of antibodies, can enable more research, shorten workflows, free up time for other tasks, and standardize results. This application note by flow robotics demonstrates the development of an automated purification solution for human IgG samples (YUMAB) using the flowbot® ONE* and PhyTip® columns. Read more
YUMAB and MOLCURE Collaborate To Advance Zero-Shot AI Antibody Discovery Technology For Undrugged Targets
YUMAB and MOLCURE Collaborate To Advance Zero-Shot AI Antibody Discovery Technology For Undrugged Targets YUMAB GmbH (“YUMAB”), a leading antibody discovery CRO headquartered in Braunschweig, Germany, and MOLCURE Inc. (“MOLCURE”), an AI-driven drug discovery company based in Kawasaki, Japan, announced their on-going collaboration now includes advancing the application of zero-shot AI technology for antibody discovery. […]
